Other inhibitors targeting the IL-1 pathway have been identified for potential applications in RA (e.g., rilonacept and an IL-1 converting enzyme inhibitor, pralnacasan), however, results to date have not demonstrated a robust clinically beneficial response (Terkeltaub et al., 2013). This evidence concerns the gene IL1B and rheumatoid arthritis.